Year 1 Adverse Events  No difference between drugs in rates of death, stroke, or myocardial infarction  Imbalance in total SAE's (mostly hospitaliza
{"Image DocumentName": "Year 1 Adverse EventsNo difference between drugs in rates of death, stroke, or myocardial infarction.", "Image ImageDescription": "Imbalance in total SAE\u2019s (mostly hospitalizations): 24% bevacizumab vs 19% ranibizumab (p=0.04) SAEs broadly distributed across all organ systems with differences present in areas not previously identified as areas of concern in systemic bevacizumab trials.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}